 |
|
|
| |
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) has Durable Efficacy and Differentiated Long-Term Safety and Tolerability Versus Efavirenz/Emtricitabine/Tenofovir DF (ATR) at Week 144 in Treatment-Naïve HIV Patients
|
| |
| |
Reported by Jules Levin
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
September 10-13, 2013Denver, CO, USA
D Wohl1, C Cohen2, JE Gallant3, A Mills4, P Sax5, E DeJesus6, A Zolopa7, HC Liu8, K White8, MS Rhee8, J Szwarcberg8
1University of North Carolina, Chapel Hill, NC, US; 2Community Research Initiative of New England, Boston, MA, US; 3Southwest CARE Center, Santa Fe, NM, US; 4Anthony Mills MD, Inc., Los Angeles, CA, US; 5Brigham and Women's Hospital, Harvard Medical School, Boston, MA, US; 6Orlando Immunology Center, Orlando, FL, US; 7Stanford University, Palo Alto, CA, US; 8Gilead Sciences, Foster City, CA, US
|
| |
|
|
|
|
|
